Contact |
General |
Specializations in Countries |
Contribution to the Global Plan |
Declaration |
View this partner's profile
Organization Contact Information |
Name: |
Centre for Infectious Disease Research in Zambia |
Street 1: |
Plot 5032 Great North Road |
Street 2: |
|
City: |
Lusaka |
Province: |
Lusaka |
Post Code: |
10101 |
Country: |
Zambia |
Phone: |
+260.211.242-257/258/259 |
Organization Email: |
info@cidrz.org |
Web Site: |
http://www.cidrz.org |
Other Online Presence: |
|
Focal Point Contact Information |
Salutation: |
Dr. |
First Name: |
Stewart |
Last Name: |
Reid |
Title: |
Senior Advisor TB Program |
Email: |
stewart.reid@cidrz.org |
Phone: |
+260 966747677 |
|
Alternate Focal Point Contact Information |
Salutation: |
Ms |
First Name: |
Sisa |
Last Name: |
Hatwiinda |
Title: |
Project Coordinator |
Email: |
sisa.hatwiinda@cidrz.org |
Phone: |
+260 979228244 |
|
General Information |
Board Constituency: |
Technical agencies |
Is your organization legally registered in your country: |
Yes |
If yes, please enter your registration number: |
|
Organization Type - Primary: |
Academic / Research Institution |
Organization Type - Secondary: |
None |
Organization Description: |
TB Research: The TB team has developed an exceptional environment for clinical research and conducts clinical trials, operations and public health research focused on the diagnosis and treatment of tuberculosis, and to assess the impact and outcomes of programmatic interventions to continually improve our activities. Studies address TB-related issues in diverse populations including prisoners, pregnant women, and HIV-infected adults and children. The CIDRZ portfolio of TB implementation science and clinical research has increased substantially over the past five years to 3.4 million USD with six funded projects. These include trials on treatment strategies for TB/HIV co-infected adult and paediatric patients (ACTG 5221, ACTG 5274), TB screening studies under the CDC-Public Health Evaluation (PHE) mechanism (LED Fluorescence microscopy field evaluations & TB screening in new ART enrollees), special populations’ studies: TB in pregnancy and Vitamin D levels in HIV/TB patients. Other TB-related research activities include field trials of Xpert MTB/RIF and development of a TB specimen repository for research on new diagnostics and biomarkers.
Laboratory Support The TB laboratory is a regional reference facility with culture and molecular diagnostic capacity. The TB laboratory can handle up to 12,000 primary specimens per year employing: 1) florescence and ZN smear microscopy, 2) liquid (MGIT 960) and solid (LJ) culture, 3) line probe assay for rapid identification of mycobacteria and drug susceptibility testing, 4) blood culture capacity and 5) first line drug susceptibility testing using liquid culture system 6) Xpert MTB/RIF. All activities are covered with two EQA programs from UK NEQAS, INSTAND (Germany) and CAP (College of American Pathologists). |
|
Do you know about the UNHLM declaration: |
|
Specializations / Areas of Work |
Advocacy Delivery of health services and care Research and Development Technical Assistance |
Other Organization Information |
Total number of staff in your organization: |
100 + |
Number of full-time staff who are directly involved with TB: |
100 + |
Number of part-time staff who are directly involved with TB: |
0 |
Number of volunteers who are directly involved with TB: |
0 |
|
How did you hear about the Stop TB Partnership: |
Stop TB communications |
If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
Why do you wish join the Stop TB Partnership: |
Information on developments within the TB world |
|
Are you a member of a Stop TB national partnership: |
No |
Are you in contact with your national TB programme: |
Yes |
Please tell us how your organization is contributing to your country's national TB control plan: |
TB Service Programs: The CIDRZ TB team works closely with the Zambian Ministry of Health and the National TB Program to improve the screening, diagnosis and management of TB in HIV-infected patients in Lusaka, Southern, Western, and Eastern provinces. This team has led the rapid scale-up of TB services in HIV-infected patients: After starting with one pilot site in late 2005, the team revamped the program and expanded support to three additional sites in 2006. By 2007, annual funding tripled to 3.8 million USD and in 2008 and 2009 we rapidly expanded throughout Lusaka, Western, and Southern provinces to 254 government health centers in 12 districts. As of 28th February, 2011 the CIDRZ TB program has trained over 1,242 health workers and is supporting provider initiated testing and counseling (PITC) programs and clinical mentoring in 23 Lusaka District health centers; 122 health centers in Southern province; 71 health centers in Western province and 43 health centers in Eastern province. Other programmatic activities include a grant to implement a sustainable TB screening program for 11,000 Zambian prisoners under the TB REACH Initiative (Stop TB Partnership, WHO), a European Union program to build capacity for oversight and coordination of prison health services in Zambia and the CDC funded – 3I’s – Implementation which include intensified community case finding, comprehensive tuberculosis control in rural Zambia using Xpert MTB/Rif and enhancing tuberculosis services in Zambian prisons. Due to the team’s collective experience in implementing TB programs and their established relationships with the NTP and other TB partners in Zambia, it is in a strong position to implement future interventions of public health importance. |
|
Geographical Reach |
Which country is your headquarters located in: |
Zambia |
Which countries do you do operate in: (This includes countries you are conducting activities in) |
Zambia |
Contribution |
Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
|
Declaration |
Declaration of interests:
none
|
Application date: |
June 25, 2010 |
Last updated: |
February 11, 2014 |
|